The Università degli Studi di Brescia has initiated a new clinical trial exploring the potential of non-invasive neuromodulation devices in managing Frontotemporal Lobar Degeneration (FTLD). This study focuses on the application of repetitive transcranial magnetic stimulation (rTMS) using a theta burst stimulation (TBS) protocol. The trial, currently recruiting participants, could offer insights into innovative therapeutic approaches for conditions associated with FTLD.
In this article:
- What changed?
- Details of the trial
- The impact on regulatory and clinical practices
- FAQs
- Conclusion
- Disclaimer
- Trial announcement link
What changed?
Frontotemporal Lobar Degeneration encompasses several neurodegenerative conditions, including Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Cortical Basal Syndrome (CBS), behavioral variant FTD (bvFTD), and Progressive Supranuclear Palsy (PSP). The introduction of devices delivering TBS protocols could reshape non-invasive therapy options. By targeting specific neural pathways, this trial aims to understand and evaluate its efficacy in disease management, marking a significant step in FTLD treatment research.
Details of the trial
This clinical trial, sponsored by the Università degli Studi di Brescia, examines two intervention types:
- Active theta burst stimulation
- Sham theta burst stimulation
Subjects will be assessed for therapeutic outcomes related to cognitive, behavioral, and motor function impairments. FTLD being a progressive condition without a cure necessitates experimental approaches. The active control design ensures robust evaluation of the device while eliminating bias.
Study framework
The protocol incorporates repetitive Transcranial Magnetic Stimulation (rTMS), focusing on modulating activity in select brain regions. Theta Burst Stimulation, a specialized form of rTMS, delivers rapid, patterned pulses thought to enhance neuroplasticity. Regulatory efforts emphasize studying safety profiles alongside performance metrics for the device.
The impact on regulatory and clinical practices
Integrating innovative technologies into FTLD trials underscores ongoing advancements in medical device regulations. For sponsors and manufacturers, this illustrates strategic compliance with scientific evidence requirements under MDR Annex XIV criteria, emphasizing plausible risk-benefit documentation.
Practitioners and clinical teams should monitor trial updates, particularly safety and performance metrics. TBS-enabled devices could influence preventive care strategies while offering complementary therapies for affected patient groups. Institutions managing these trials must align reporting practices with official regulatory standards to support further progress.
FAQs
1. What is theta burst stimulation?
It is a form of repetitive Transcranial Magnetic Stimulation designed to deliver precise, patterned pulses targeting brain regions. Theta burst protocols are studied for their potential impact on neural plasticity.
2. Who can participate in this study?
Recruitment details and eligibility requirements may be available on the ClinicalTrials.gov page linked below. The trial appears focused on conditions under FTLD.
3. Are there risks associated with rTMS?
rTMS is considered a low-risk intervention. However, safety evaluations remain a cornerstone of trial designs, ensuring adverse effects are identified and minimized.
Conclusion
The Università degli Studi di Brescia’s trial reinforces the focus on integrating non-invasive medical devices addressing neurodegenerative conditions like FTLD. As TBS protocols gain interest, results of this study could inform new regulatory pathways while shaping therapeutic applications.
Disclaimer
This information targets healthcare professionals and researchers. It is not legal advice or official guidance. Readers should consult regulatory authorities or legal experts for compliance questions related to medical device trials.
Trial announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07316413?term=medical+device